Innovator U.S. Equity Buffer ETF - February (BATS: BFEB)

Latest news for Innovator U.S. Equity Buffer ETF - February (BATS:BFEB)

The Fund invests at least 80% of its net assets in FLexible EXchange Options (FLEX Options) that reference the SPDR S&P 500 ETF Trust (the Underlying ETF). FLEX Options are exchange-traded option contracts with uniquely customizable terms. Although guaranteed for settlement by the Options Clearing Corporation (the OCC), FLEX Options are still subject to counterparty risk with the OCC and may be less liquid than more traditional exchange-traded option contracts. 

Innovator US Equity Buffer ETF - February

Innovator U.S. Equity Buffer ETF - February

CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>) has been analyzed by 3 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $28.33, a high estimate of $35.00, and a low estimate of $24.00. A 9.58% drop is evident in the current average compared to the previous average price target of $31.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1736942410_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of CareDx among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$24.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Yi Chen</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$35.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CareDx. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of CareDx compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for CareDx's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into CareDx's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CDNA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CareDx analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>All You Need to Know About CareDx</h2>
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
<h3>CareDx: A Financial Overview</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining CareDx's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 23.35% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: CareDx's net margin is impressive, surpassing industry averages. With a net margin of -8.94%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): CareDx's ROE excels beyond industry benchmarks, reaching -2.75%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): CareDx's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -1.57%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.11.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

CDNA

Breaking Down CareDx: 3 Analysts Share Their Views

EV giant Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) reportedly plans to suspend parts of its manufacturing lines in Shanghai dedicated to making its <a href="https://www.benzinga.com/tech/25/01/42905406/tesla-launches-refreshed-model-y-in-china-amid-rising-competition">refreshed Model Y SUV</a>.
What Happened: Tesla is planning to suspend part of the lines for its refreshed Model Y for around three weeks over Chinese New Year, Bloomberg News <a href="https://www.bloomberg.com/news/articles/2025-01-15/tesla-to-suspend-part-of-new-model-y-lines-in-china-for-upgrades">reported</a>, citing people familiar with the matter. The suspension is aimed at prepping the lines for ramped-up production of the new model, the report said.
The pause on parts of the Model Y lines will be from Jan. 22 through Feb. 14, the report said while adding that another portion of the factory that makes the company&#8217;s Model 3 sedans will also be closed from Jan. 26 to Feb. 3. 
Tesla did not immediately respond to <a href="https://www.benzinga.com/pro/">Benzinga&#8217;s</a> request for comment.
Why It Matters: Tesla launched its refreshed Model Y in China last week. The refreshed vehicle starts at 263,500 yuan on Tesla's website, nearly 5.4% pricier than the older version of the vehicle which started at 249,900 yuan.
The new Model Y, Tesla says on the website, has a "longer range, new design and higher quality interior," among other changes. Deliveries of the new vehicle are expected to start in March.
The launch of a refreshed Model Y in a key market follows Tesla&#8217;s first annual decline in vehicle deliveries in over a decade. Tesla reported global&nbsp;<a href="https://www.benzinga.com/trading-ideas/movers/25/01/42766117/tesla-stock-tumbles-on-q4-deliveries-whats-going-on" target="_blank" rel="noreferrer noopener">deliveries of 1.79 million</a>&nbsp;vehicles in 2024, down from full-year deliveries of 1.81 million in 2023.
Chinese EV giant BYD Co Ltd is also fast closing in on Tesla&#8217;s position as the world&#8217;s best-selling battery electric vehicle brand. BYD delivered over 1.76 million BEVs&nbsp;in 2024, only 24,234 units less than Tesla.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42967593/cybertruck-sales-rise-in-2024-weighed-down-on-tesla-model-s-deliveries-in-us-shows-data" target="_blank" rel="noreferrer noopener">Cybertruck Success Comes At A Cost: Tesla Sells Nearly 39,000 Units In 2024, But Luxury Model S And X Sales Take A Hit In US, Data Shows</a></li>
</ul>
Photo courtesy: Tesla

Tech

Media

TSLA

Tesla To Suspend Parts Of Refreshed Model Y Lines In Shanghai For 3 Weeks: Report

Needham analyst Scott Berg reiterates Thryv Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRY#NASDAQ">THRY</a>) with a Buy and maintains $28 price target.

News

Price Target

Reiteration

THRY

Needham Reiterates Buy on Thryv Holdings, Maintains $28 Price Target

B of A Securities analyst Lorraine Hutchinson maintains Signet Jewelers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) with a Neutral and lowers the price target from $95 to $65.

B of A Securities Maintains Neutral on Signet Jewelers, Lowers Price Target to $65

HC Wainwright &amp; Co. analyst Ed Arce maintains Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) with a Buy and raises the price target from $18 to $22.

TVTX

HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Raises Price Target to $22

Endeavour Silver Corporation Provides 2025 Guidance For Guanaceví And Bolañitos; Production Expected At 4.5M-5.2M OZ Silver And 30,500-34,000 OZ Gold For 7M–7.9M OZ Silver Equivalent

HC Wainwright &amp; Co. analyst Edward White reiterates TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) with a Buy and maintains $55 price target.

TGTX

HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $55 Price Target

Investment giant&nbsp;BlackRock, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) stock is trading higher after the company&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42996688/blackrock-reports-full-year-2024-diluted-eps-of-42-01-or-43-61-as-adjusted-fourth-quarter-2024-dil" rel="noreferrer noopener">reported&nbsp;fourth-quarter&nbsp;results</a>.
Revenue grew 23% year over year to&nbsp;$5.68 billion, beating the consensus of&nbsp;$5.53 billion.&nbsp;
Investment advisory, administration fees, and securities lending revenues increased to&nbsp;$4.4 billion&nbsp;from&nbsp;$3.6 billion&nbsp;a year ago, led by higher organic base fee, the impact of market beta on average AUM and, around $230 million of fees related to AUM acquired in the GIP Transaction.
Technology services revenue rose to&nbsp;$428 million&nbsp;from&nbsp;$379 million&nbsp;the prior year, led by the successful onboarding of several new clients.
BlackRock stated that net inflow stood at&nbsp;$281 billion&nbsp;in the quarter and $641 billion in 2024.
Total AUM stood at&nbsp;$11.6 trillion at the end of the year compared to $10.0 trillion in 2023.
Adjusted operating income rose&nbsp;36%&nbsp;Y/Y to&nbsp;$2.33 billion, with the margin expanding to&nbsp;45.5%&nbsp;from&nbsp;41.6%&nbsp;a year ago.
Adjusted EPS increased&nbsp;23%&nbsp;Y/Y to&nbsp;$11.93,&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating the consensus of&nbsp;$11.21.</a>
BlackRock repurchased shares worth&nbsp;$1.6 billion in the year.&nbsp;
Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/01/42984073/banks-kick-off-earnings-season-on-wednesday-retail-traders-bet-big-on-financials-ahead-of-regulatory-tailwinds" rel="noreferrer noopener">Banks Kick Off Earnings Season On Wednesday: Retail Traders Bet Big On Financials Ahead Of Regulatory Tailwinds</a>
Laurence D. Fink, Chairman and CEO, said,&nbsp;&#8220;Client activity accelerated into the fourth quarter, resulting in 7% organic base fee growth and 12% technology services ACV growth.&#8221;
In December 2024, the company disclosed a definitive agreement to acquire&nbsp;HPS Investment&nbsp;Partners&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42296768/blackrock-makes-12-billion-power-move-acquires-hps-to-bolster-private-credit-offerings" rel="noreferrer noopener">for around $12 billion</a>.
This transaction strengthens BlackRock&#8217;s offerings for insurance clients. The deal is expected to increase private markets fee-paying AUM and management fees by 40% and 35%, respectively, and be modestly accretive to BlackRock&#8217;s as-adjusted earnings&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">per share in the first full year post-close</a>.
Fink added, &#8220;Our record organic growth and financial results do not yet reflect the full integration or pending acquisitions of the high-growth businesses of GIP, HPS and Preqin. And we&#8217;ve steadily made organic investments ahead of structural trends that we expect to drive outsized growth in the years ahead.&#8221;
Investors can gain exposure to the stock via&nbsp;Fidelity Disruptive Finance ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDFF#NASDAQ">FDFF</a>) and&nbsp;Schwab US Dividend Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>).
Price Action: BLK shares are up 2.38% at $986.12 premarket at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/42910264/trump-fallout-blackrock-exits-climate-alliance-cites-regulatory-pressure-and-client-confusion" target="_blank" rel="noreferrer noopener">Trump Fallout? BlackRock Exits Climate Alliance, Cites Regulatory Pressure And Client Confusion</a></li>
</ul>
Photo by rafapress on Shutterstock.

Earnings

Equities

Large Cap

Movers

FDFF

SCHD

BlackRock Q4 Earnings: Record Inflows Fuel Revenue And Earnings Beat, AUM Hits $11.6 Trillion Milestone

As part of the company's 2024 investment of more than $10 million to expand manufacturing capacity, new needle and syringe production lines have been installed at the BD plants in Connecticut and Nebraska. One line is already fully operational with additional lines expected to start up in the coming months.
These new lines will boost BD's capacity of domestically manufactured safety-engineered injection devices by more than 40 percent and conventional syringes by more than 50 percent, adding hundreds of millions of units annually to support critical U.S. health care delivery such as hospital procedures, vaccinations, medication preparation and drug delivery to patients. In addition, BD has hired more than 215 full-time employees at its facilities in Nebraska and Connecticut to support the increased production.

Becton, Dickinson And Company Says It Boosts US Manufacturing Of Critical Medical Devices: Among Others Company Plans Over $30M In Investments In 2025 To Expand Manufacturing Capacity For IV Lines At Its Plant In Utah   To Support Continued Growth In Catheter Solutions

WIIM

JPMorgan Chase shares are trading higher after the company reported better-than-expected Q4 EPS and revenues.

Janney Montgomery Scott analyst Robert Stevenson downgrades Douglas Emmett (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEI#NYSE">DEI</a>) from Buy to Neutral.

Downgrades

Janney Montgomery Scott Downgrades Douglas Emmett to Neutral

HC Wainwright &amp; Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) with a Buy and maintains $7 price target.

KPTI

HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $7 Price Target

Wells Fargo Q4 Net Interest Income Decreased 7% YoY

DA Davidson analyst Michael Shlisky upgrades Shyft Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHYF#NASDAQ">SHYF</a>) from Neutral to Buy and maintains the price target from $15 to $15.

Upgrades

SHYF

DA Davidson Upgrades Shyft Group to Buy, Maintains Price Target to $15

MNSO

MINISO Says It Launched Flagship Store In Thailand, Building Another Landmark In SE Asia

HC Wainwright &amp; Co. analyst Heiko Ihle maintains Integra Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ITRG#AMEX">ITRG</a>) with a Buy and lowers the price target from $3.75 to $2.

ITRG

HC Wainwright & Co. Maintains Buy on Integra Resources, Lowers Price Target to $2

As the weekend approaches, TikTok is on the verge of being banned in the United States unless the Supreme Court steps in to halt the process. 
What Happened: The potential ban of TikTok on Sunday could impact the app&#8217;s nearly 17,000 employees in the U.S., sparking a wave of uncertainty.
In the latter half of 2024, TikTok saw a 38% rise in employee departures compared to the same period in 2023, as per <a href="https://www.adweek.com/media/tiktoks-us-hiring-slowed/">Adweek</a>. Many former employees have transitioned to major tech companies such as Meta, Google, Amazon, Microsoft, and Apple.
Despite the increase in departures, TikTok&#8217;s hiring has&nbsp;slowed to its lowest level&nbsp;since 2020, with over 2,000 job openings still listed on its career site across various U.S. cities, covering roles in&nbsp;product, design, operations, advertising, and&nbsp;sales.
TikTok reportedly reassured its U.S. employees that their &#8220;employment, pay, and benefits are secure, and our offices will remain open, even if this situation hasn&#8217;t been resolved before the January 19 deadline,&#8221; Business Insider <a href="https://www.businessinsider.com/tiktok-tells-staff-still-have-jobs-if-ban-happens-memo-2025-1">reported</a> on Wednesday. 
The memo also noted that only the U.S. user experience would be impacted.
As TikTok awaits the Supreme Court&#8217;s decision, the company is preparing for various outcomes. Legal analysts suggest that the court is unlikely to overturn the existing ruling. Meanwhile, President-elect Donald Trump has expressed intentions to save the app once in office.
Why It Matters: The potential TikTok ban in the U.S. has been a topic of significant discussion, with the&nbsp;<a href="https://www.benzinga.com/general/social-media/25/01/42957741/tiktok-ban-deadline-ahead-what-will-happen-to-app-on-your-phone">Supreme Court</a>&nbsp;signaling support for enforcing the<a href="https://www.benzinga.com/general/social-media/25/01/42957741/tiktok-ban-deadline-ahead-what-will-happen-to-app-on-your-phone"> Jan. 19 deadline</a>. This has led to various speculations about what might happen to the app on users&#8217; phones and which companies could benefit from the ban.
In a surprising development,&nbsp;Elon Musk&nbsp;has emerged as a potential buyer for <a href="https://www.benzinga.com/general/social-media/25/01/42965533/elon-musk-emerges-as-potential-tiktok-us-buyer-as-ban-deadline-looms-company-terms-it-pure-fiction">TikTok&#8217;s U.S. operations</a>. Discussions, though preliminary, suggest a potential scenario where Musk's X platform could acquire TikTok's U.S. operations, valued between $40 billion to $50 billion. This move would merge TikTok's 170 million U.S. users with X's advertising reach.
Additionally,&nbsp;YouTuber MrBeast has also <a href="https://www.benzinga.com/general/social-media/25/01/42994923/mrbeast-discussing-buying-tiktok-with-billionaires-to-prevent-us-shutdown-lets-see-if-we-can-pull-this-off">expressed interest in acquiring TikTok </a>to prevent its shutdown. He is reportedly in talks with several billionaires to explore the feasibility of this purchase, although no names have been disclosed yet.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42988409/bitcoin-ethereum-xrp-dogecoin-move-higher-ahead-of-inflation-data-wednesday">Bitcoin, Ethereum, XRP, Dogecoin Move Higher Ahead Of Inflation Data Wednesday</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Social Media

General

TikTok Is Set To Be Banned In The US This Sunday Unless The Supreme Court Steps In: Here's What Happens To Its Nearly 17,000 American Workforce

JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) reported quarterly earnings of $4.81 per share which beat the analyst consensus estimate of $4.11 by 17.03 percent. The company reported quarterly sales of $43.738 billion which beat the analyst consensus estimate of $41.707 billion by 4.87 percent. This is a 9.50 percent increase over sales of $39.943 billion the same period last year.

Earnings Beats

JPMorgan Chase Q4 2024 GAAP EPS $4.81 Beats $4.11 Estimate, Sales $43.738B Beat $41.707B Estimate

Wells Fargo shares are trading higher following a Q4 EPS beat.

The most oversold stocks in the communication services sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">IAC Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAC#NASDAQ">IAC</a>)</h3>
<ul>
<li>After the market close on Monday, IAC announced its board approved a plan to spin off its full stake in Angi to IAC shareholders. As part of the change, IAC CEO Joey Levin will leave his role and become an advisor to the company. Levin will also be named executive chairman of Angi. "Joey Levin has wanted a store of his own for some time and the spin-off of Angi affords him this opportunity. Although IAC will relinquish his services as CEO, we expect that he will continue to advise us for many years," said Barry Diller, senior executive and chairman of IAC. The company' stock fell around 7% over the past month and has a <a href="https://www.benzinga.com/quote/IAC">52-week low of $39.61</a>.</li>
<li>RSI Value: 28.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>IAC Price Action: Shares of IAC gained 0.4% to close at $41.65 on Tuesday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1">latest IAC news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="910" height="857" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15064428/image-92.png" alt="" class="wp-image-734460" style="width:579px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15064428/image-92.png 910w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15064428/image-92-300x283.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15064428/image-92-768x723.png 768w" sizes="(max-width: 910px) 100vw, 910px" /></a></figure>
<h3 class="wp-block-heading">Fubotv Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NYSE">FUBO</a>)</h3>
<ul>
<li>On Jan. 6, FuboTV, along with The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>), finalized a definitive agreement to combine Disney's Hulu + Live TV with Fubo, forming a combined virtual MVPD company. The company's stock fell around 29% over the past five days and <a href="https://www.benzinga.com/quote/FUBO">has a 52-week low</a> of $1.10.</li>
<li>RSI Value: 19.2</li>
<li>FUBO Price Action: Shares of Fubotv fell 14.4% to close at $3.81 on Tuesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1">FUBO stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="927" height="852" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15064524/image-93.png" alt="" class="wp-image-734461" style="width:608px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15064524/image-93.png 927w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15064524/image-93-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15064524/image-93-768x706.png 768w" sizes="(max-width: 927px) 100vw, 927px" /></a></figure>
<h3 class="wp-block-heading">Getty Images Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>)</h3>
<ul>
<li>On Jan. 7, Getty Images and Shutterstock announced a $3.7 billion merger. The company's stock fell around 30% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/GETY">low of $2.06.</a></li>
<li>RSI Value: 24</li>
<li>GETY Price Action: Shares of Getty Images gained 5.7% to close at $2.58 on Tuesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1">GETY shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="892" height="848" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15064619/image-94.png" alt="" class="wp-image-734462" style="width:548px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15064619/image-94.png 892w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15064619/image-94-300x285.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15064619/image-94-768x730.png 768w" sizes="(max-width: 892px) 100vw, 892px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/01/42992639/how-to-earn-500-a-month-from-state-street-stock-ahead-of-q4-earnings">How To Earn $500 A Month From State Street Stock Ahead Of Q4 Earnings</a></li>
</ul>

Comments

Innovator U.S. Equity Buffer ETF - February

News

Latest news for Innovator U.S. Equity Buffer ETF - February (BATS:BFEB)

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga